These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 31368758)

  • 21. Aβ-related memory decline in APOE ε4 noncarriers: Implications for Alzheimer disease.
    Lim YY; Laws SM; Villemagne VL; Pietrzak RH; Porter T; Ames D; Fowler C; Rainey-Smith S; Snyder PJ; Martins RN; Salvado O; Bourgeat P; Rowe CC; Masters CL; Maruff P
    Neurology; 2016 Apr; 86(17):1635-42. PubMed ID: 27029632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebral Blood Flow and Amyloid-β Interact to Affect Memory Performance in Cognitively Normal Older Adults.
    Bangen KJ; Clark AL; Edmonds EC; Evangelista ND; Werhane ML; Thomas KR; Locano LE; Tran M; Zlatar ZZ; Nation DA; Bondi MW; Delano-Wood L
    Front Aging Neurosci; 2017; 9():181. PubMed ID: 28642699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decline in cognitive function over 18 months in healthy older adults with high amyloid-β.
    Ellis KA; Lim YY; Harrington K; Ames D; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Maruff P;
    J Alzheimers Dis; 2013; 34(4):861-71. PubMed ID: 23302660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months.
    Thai C; Lim YY; Villemagne VL; Laws SM; Ames D; Ellis KA; Rainey-Smith SR; Martins RN; Masters CL; Rowe CC; Maruff P;
    PLoS One; 2015; 10(10):e0139082. PubMed ID: 26430784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amyloid-β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults.
    Hollands S; Lim YY; Buckley R; Pietrzak RH; Snyder PJ; Ames D; Ellis KA; Harrington K; Lautenschlager N; Martins RN; Masters CL; Villemagne VL; Rowe CC; Maruff P
    J Alzheimers Dis; 2015; 43(2):677-86. PubMed ID: 25114076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden.
    Rembach A; Watt AD; Wilson WJ; Villemagne VL; Burnham SC; Ellis KA; Maruff P; Ames D; Rowe CC; Macaulay SL; Bush AI; Martins RN; Masters CL; Doecke JD;
    J Alzheimers Dis; 2014; 40(1):95-104. PubMed ID: 24334723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid decline in episodic memory in healthy older adults with high amyloid-β.
    Lim YY; Pietrzak RH; Ellis KA; Jaeger J; Harrington K; Ashwood T; Szoeke C; Martins RN; Bush AI; Masters CL; Rowe CC; Villemagne VL; Ames D; Darby D; Maruff P
    J Alzheimers Dis; 2013; 33(3):675-9. PubMed ID: 23001710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amyloid burden and incident depressive symptoms in preclinical Alzheimer's disease.
    Perin S; Harrington KD; Lim YY; Ellis K; Ames D; Pietrzak RH; Schembri A; Rainey-Smith S; Salvado O; Laws SM; Martins RN; Villemagne VL; Rowe CC; Masters CL; Maruff P;
    J Affect Disord; 2018 Mar; 229():269-274. PubMed ID: 29329059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis.
    Baker JE; Lim YY; Pietrzak RH; Hassenstab J; Snyder PJ; Masters CL; Maruff P
    Alzheimers Dement (Amst); 2017; 6():108-121. PubMed ID: 28239636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subthreshold Amyloid Predicts Tau Deposition in Aging.
    Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ
    J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amyloid burden and incident depressive symptoms in cognitively normal older adults.
    Harrington KD; Gould E; Lim YY; Ames D; Pietrzak RH; Rembach A; Rainey-Smith S; Martins RN; Salvado O; Villemagne VL; Rowe CC; Masters CL; Maruff P;
    Int J Geriatr Psychiatry; 2017 Apr; 32(4):455-463. PubMed ID: 27114112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. APOEɛ4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults.
    Hollands S; Lim YY; Laws SM; Villemagne VL; Pietrzak RH; Harrington K; Porter T; Snyder P; Ames D; Fowler C; Rainey-Smith SR; Martins RN; Salvado O; Robertson J; Rowe CC; Masters CL; Maruff P;
    J Alzheimers Dis; 2017; 57(2):411-422. PubMed ID: 28234254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.
    Chatterjee P; Elmi M; Goozee K; Shah T; Sohrabi HR; Dias CB; Pedrini S; Shen K; Asih PR; Dave P; Taddei K; Vanderstichele H; Zetterberg H; Blennow K; Martins RN
    J Alzheimers Dis; 2019; 71(3):775-783. PubMed ID: 31424403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia.
    Zhao Y; Tudorascu DL; Lopez OL; Cohen AD; Mathis CA; Aizenstein HJ; Price JC; Kuller LH; Kamboh MI; DeKosky ST; Klunk WE; Snitz BE
    JAMA Neurol; 2018 Jan; 75(1):88-96. PubMed ID: 29114732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study.
    Pietrzak RH; Lim YY; Neumeister A; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Restrepo C; Martins RN; Masters CL; Villemagne VL; Rowe CC; Maruff P;
    JAMA Psychiatry; 2015 Mar; 72(3):284-91. PubMed ID: 25629787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subjective Memory Complaints in APOEɛ4 Carriers are Associated with High Amyloid-β Burden.
    Zwan MD; Villemagne VL; Doré V; Buckley R; Bourgeat P; Veljanoski R; Salvado O; Williams R; Margison L; Rembach A; Macaulay SL; Martins R; Ames D; van der Flier WM; Ellis KA; Scheltens P; Masters CL; Rowe CC
    J Alzheimers Dis; 2016; 49(4):1115-22. PubMed ID: 26639956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging.
    Maass A; Lockhart SN; Harrison TM; Bell RK; Mellinger T; Swinnerton K; Baker SL; Rabinovici GD; Jagust WJ
    J Neurosci; 2018 Jan; 38(3):530-543. PubMed ID: 29192126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β-Associated Cognitive Decline in Older Adults.
    Dang C; Harrington KD; Lim YY; Ames D; Hassenstab J; Laws SM; Yassi N; Hickey M; Rainey-Smith SR; Robertson J; Rowe CC; Sohrabi HR; Salvado O; Weinborn M; Villemagne VL; Masters CL; Maruff P;
    Arch Clin Neuropsychol; 2019 Jul; 34(5):585-598. PubMed ID: 30272115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.